amgen inc (AMGN:NASDAQ GS)
As of 8:10 PM 05/21/13 All times are local (Market data is delayed by at least 15 minutes).
Financial Statements for amgen inc (AMGN)
Year over year, Amgen Inc. has been able to grow revenues from $15.3B USD to $16.6B USD. Most impressively, the company has been able to reduce the percentage of sales devoted to selling, general and administrative costs from 29.33% to 28.85%. This was a driver that led to a bottom line growth from $3.7B USD to $4.3B USD.
| Currency in Millions of US Dollars | As of: | Dec 31 2009 Reclassified | Dec 31 2010 | Dec 31 2011 | Dec 31 2012 | 4 Year Trend |
| Revenues | 14,351.0 | 14,660.0 | 15,295.0 | 16,639.0 |  | |
| TOTAL REVENUES | 14,642.0 | 15,053.0 | 15,582.0 | 17,265.0 | | |
| Cost of Goods Sold | 2,091.0 | 2,220.0 | 2,404.0 | 2,800.0 | | |
| GROSS PROFIT | 12,551.0 | 12,833.0 | 13,178.0 | 14,465.0 | | |
| Selling General & Admin Expenses, Total | 3,788.0 | 3,983.0 | 4,486.0 | 4,801.0 | | |
| R&D Expenses | 2,864.0 | 2,894.0 | 3,167.0 | 3,380.0 | | |
| Depreciation & Amortization, Total | 294.0 | 294.0 | 294.0 | 294.0 | | |
| Other Operating Expenses | 9.0 | -1.0 | 7.0 | 6.0 | | |
| OTHER OPERATING EXPENSES, TOTAL | 6,955.0 | 7,170.0 | 7,954.0 | 8,481.0 | | |
| OPERATING INCOME | 5,596.0 | 5,663.0 | 5,224.0 | 5,984.0 | | |
| Interest Expense | -578.0 | -604.0 | -610.0 | -1,053.0 | | |
| Interest and Investment Income | 258.0 | 254.0 | 298.0 | 273.0 | | |
| Other Non-Operating Expenses, Total | -24.0 | 32.0 | -4.0 | 80.0 | | |
| Merger & Restructuring Charges | -57.0 | -118.0 | -132.0 | -293.0 | | |
| Gain (Loss) on Sale of Investments | 42.0 | 90.0 | 154.0 | 132.0 | | |
| Other Unusual Items, Total | -33.0 | -- | -780.0 | -114.0 | | |
| EBT, INCLUDING UNUSUAL ITEMS | 5,204.0 | 5,317.0 | 4,150.0 | 5,009.0 | | |
| Income Tax Expense | 599.0 | 690.0 | 467.0 | 664.0 | | |
| Earnings from Continuing Operations | 4,605.0 | 4,627.0 | 3,683.0 | 4,345.0 | | |
| NET INCOME | 4,605.0 | 4,627.0 | 3,683.0 | 4,345.0 | | |
| NET INCOME TO COMMON INCLUDING EXTRA ITEMS | 4,605.0 | 4,627.0 | 3,683.0 | 4,345.0 | | |
| NET INCOME TO COMMON EXCLUDING EXTRA ITEMS | 4,605.0 | 4,627.0 | 3,683.0 | 4,345.0 | | |
| Recently Viewed | |||
| AMGN:US | $104.24 USD | +2.06 |  |
| Company | Last | Change |
| 3M Co | $112.01 USD | +0.29 |
| AbbVie Inc | $46.54 USD | +0.28 |
| Bristol-Myers Squibb Co | $44.06 USD | +0.30 |
| Eli Lilly & Co | $55.14 USD | +0.12 |
| Gilead Sciences Inc | $56.47 USD | +0.73 |
| View Industry Companies | ||
Industry Analysis
AMGN
Industry Average
| Valuation | AMGN | Industry Range |
| Price/Earnings | 17.3x |
|
| Price/Sales | 4.4x |
|
| Price/Book | 3.9x |
|
| Price/Cash Flow | 15.7x |
|
| TEV/Sales | 1.8x |
|
Post a JobJobs
- California | AmgenPosted: May 21
- Thousand Oaks, CA | AmgenPosted: May 19
- California | AmgenPosted: May 21
- California | AmgenPosted: May 21
